MSN Pharmaceuticals Inc completes its maiden US FDA audit with zero observations
The state-of-the-art finished dosages facility was established to bolster MSN Group’s product portfolio as well as Contract Development and Manufacturing services, in the US and several other key regulatory markets
MSN Pharmaceuticals Inc has completed its maiden US Food and Drug Administration (FDA) audit with zero observations, the company notified via a statement.
The dosages facility was established to bolster MSN Group’s product portfolio as well as Contract Development and Manufacturing services, in the US and several other key regulatory markets, the statement said.
- Advertisement -